The FDA in 2016 granted accelerated approval to the FXR agonist as a second-line treatment for adults with PBC, either in ...
Senescence, in which cells become tired and stop working effectively, is a common effect of ageing, but can also be triggered ...
On Friday, Gilead Sciences, Inc. (NASDAQ:GILD) revealed data from a two-and-a-half-year interim analysis from the ongoing ...
A two-year liver health project is underway across the Humber region, aiming to enhance patient care, reduce emergency ...
The U.S. Food and Drug Administration on Tuesday declined full approval for Intercept Pharmaceuticals' liver disease drug, ...
Liver disease, which is treatable when discovered early, often goes undetected until late stages, but a new study revealed that an algorithm fueled by artificial intelligence can accurately detect ...
By 2018, federal data showed that 42% of adults had some form of fatty liver disease -- higher than prior estimates, ...
As the prevalence of obesity, alcohol use, and liver disease increases, physicians should take note of patients' lifestyle ...
“With a better understanding of risk, clinicians can prioritize their approach to treatment and prevention of metabolic ...
Cardiovascular disease (CVD) is the most common cause of death in NAFLD patients. Liver biopsy and noninvasive markers should be used to stage and grade nonalcoholic steatohepatitis (NASH ...
Primary biliary cholangitis (PBC) has typically been considered a rare condition, with a pooled global estimated incidence of ...